ADAR1 Capital Management »

Alnylam Pharmaceuticals shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Alnylam Pharmaceuticals (ALNY) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Alnylam Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Alnylam Pharmaceuticals held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Alnylam Pharmaceuticals by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $64M 426k 149.45
2023-12-31 $46M 238k 191.41

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Alnylam Pharmaceuticals

Capital World Investors
Vanguard Group
BlackRock
BlackRock
Capital Research Global Investors
Baillie Gifford & Co
Capital Research and Management Company - Division 3
Dodge & Cox
State Street Corporation
T. Rowe Price Associates
T. Rowe Price Investment Management
Jpmorgan Chase & Co
Geode Capital Management
American Century Companies
Groupama Asset Managment

View all funds holding Alnylam Pharmaceuticals